Precision-Controlled Antigens Detail B Cell Activation

A new study from Aarhus University challenges traditional beliefs about the immune system’s activation method for B cells. The team, whose study was published in Nature Communications, reveals that even antigens that can only bind one receptor at a time can activate B cells, contrary to what was previously believed.

This discovery provides a breakthrough in our understanding of how immune cells recognize pathogens, which can lead to better vaccine design. The study also sheds new light on the foundation for how receptors on the surface of cells send signals into the cells, a crucial biological process.

By leveraging a Holliday junction nanoscaffold, the scientists engineered monodisperse model antigens with precision-controlled affinity and valency. They found that the antigen exerts agonistic effects on the BCR as a function of increasing affinity and avidity. Additionally, they discovered that monovalent macromolecular antigens can activate the BCR at high concentrations, but micromolecular antigens cannot.

The humoral branch of the adaptive immune system plays a central role in combating pathogens by producing antibodies and immunological memory governed by B cells. The study’s findings uncover a new perspective on one of the most critical processes in the immune system. The researchers are attempting to use the same tools in reverse to turn off harmful immune system responses such as allergic reactions and autoimmune diseases.

These findings provide a new model that can be used to create better vaccines and treatments for a large group of diseases. The team is currently conducting preclinical vaccine trials to translate their findings into clinically relevant vaccine designs. The study is an exciting breakthrough that challenges the old paradigm and opens the door to new possibilities in vaccine design and therapies for autoimmune diseases and allergies.